Bionomics Completes Enrolment for BNC105 Phase II Renal Cancer Trial ADELAIDE, South Australia -- Bionomics Limited (ASX:BNO) has completed enrolment into a randomized Phase II clinical trial testing the combination of BNC105 plus everolimus (Afinitor) to treat patients ...
June 11, 2013 - GlobeNewswire via Yahoo! Finance